Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

81 results about "Bordetella" patented technology

Bordetella (/ˌbɔːrdəˈtɛlə/) is a genus of small (0.2 – 0.7 µm), Gram-negative coccobacilli of the phylum Proteobacteria. Bordetella species, with the exception of B. petrii, are obligate aerobes, as well as highly fastidious, or difficult to culture. All species can infect humans. The first three species to be described (B. pertussis, B. parapertussis, B. bronchiseptica); are sometimes referred to as the 'classical species'. Two of these (B. bronchiseptica and B. pertussis) are also motile.

Recombinant proteins of filamentous haemagglutinin of bordetella, particularly bordetella pertussis, method for producing same, and uses thereof for producing foreign proteins of vaccinating active principles

A recombinant DNA containing a sequence (1) coding for a polypeptide heterologous to a filamentous haemagglutinin of Bordetella (Fha) fused within the reading frame to a sequence (2) located upstream from the first sequence. Sequence (2) codes for at least part of the Fha precursor, which part comprises at least the N-terminal region of a truncated mature Fha protein, which contains the interaction site of Fha and heparin and the secretion domain. This Fha protein is under the control of a promoter recognized by the cell polymerases of B. pertussis and is inserted into a B. pertussis cell culture, is expressed in the culture and excreted into the cell culture medium. The invention uses both the abilities of Bordetella and particularly B. pertussis to secrete or surface expose the heterologous polypeptide fused to the Fha portion corresponding to sequence (2), which does not appear to produce extracellular proteases, and the ease with which filamentous haemagglutinins can be isolated from other Bordetella proteins.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1

Acellular antibordetella vaccine

InactiveUS6387377B1Antibacterial agentsBiocideCyclaseBronchial sepsis
The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B. Tertussis, B. parapertussis or B. bronchiseptica, and in that it comprises, in addition, a bacterial extract containing the expression products of the vrg genes of a strain of Bordetella chosen from B. pertussis, B. parapertussis or B. bronchiseptica, or a portion of these expression products which is sufficient to induce an immune response in a host to which the extract might be administered.
Owner:INST PASTEUR

Immunogenic Bordetella Bronchiseptica Compositions

Provided herein are compositions, combinations, and methods comprising Bordetella bronchiseptica and isolated pertactin, which are effective in treating or preventing respiratory infections, such as kennel cough, in animals.
Owner:ZOETIS SERVICE LLC

Recombinant salmonella choleraesuis strain for expression of pig origin bordetella bronchisepatica fhaB and prn gene segment, bacterin and uses thereof

The invention pertains to the animal bacteria gene engineering field, relating to construction, vaccine preparation and application of salmonella choleraesuis of recombinant porcine with fhaB and prn gene fragment of porcine bordetella bronchiseptica from expression which contains no resistance markers. A strain of salmonella choleraesuis of recombinant porcine of C501 (pYA-F1P2 (preservation number is: CCTCC NO: M207138) with fhaB and prn gene fragment of porcine bordetella bronchiseptica from expression which contains no resistance markers is provided by the invention. The stain of asd gene lacks of samonella choleraesuis, and contains plasmid of pYA-F1P2 which can express asd in the strain and fhaB and prn gene fragment of porcine bordetella bronchiseptica. The invention discloses a preparation method of the recombination stain and vaccine and application in the preparation of the vaccine of the porcine salmonella choleraesuis and the porcine bordetella bronchiseptica. The gene engineering vaccine of the invention can stimulate porcine to produce an immune reaction to protect porcine from the salmonella choleraesuis and the porcine bordetella bronchiseptica and can effectively prevent from being infected by the salmonella choleraesuis and the porcine bordetella bronchiseptica.
Owner:WUHAN KEQIAN BIOLOGY CO LTD

Immunogenic compositions for use in vaccination against bordetella

The present application relates to immunogenic compositions comprising a mixture of Bordetella (e.g., B. pertussis) antigens and an oil in water nanoemulsion. In particular, the invention provides immunogenic compositions comprising nanoemulsion and a combination of Bordetella (e.g., B. pertussis) antigens that have different functions, for example, combinations including B. pertussis adherence factors (adhesins), B. pertussis toxins or B. pertussis virulence factors. Vaccines, methods of treatment, uses of and processes to make a pertussis or whooping cough vaccine are also described. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
Owner:NANOBIO CORP +1

Influenza vaccine, composition, and methods of use

The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and / or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
Owner:INSTITUT PASTEUR DE LILLE +2

Expression of gene products from genetically manipulated strains of bordetella

An expression system for expressing gene products from recombinant Bordetella strains and specific nucleic acid molecules useful in transforming Bordetella strains for such expression are described. A nucleic acid molecule may comprise a Bordetella promoter operatively coupled to a heterologous gene encoding a non-Bordetella gene product with the heterologous gene transcriptionally regulated by the Bordetella promoter. The nucleic acid molecule may further comprise a further nucleic acid molecule encoding a leader sequence for secretion of the non-Bordetella gene product. Another nucleic acid molecule may comprise a Bordetella promoter coupled to a nucleic acid sequence encoding a non-Bordetella leader sequence for secretion of a gene product, which may be a Bordetella gene product or a non-Bordetella gene product.
Owner:CONNAUGHT LAB

Haemophilus parasuis outer membrane protein P5 (OMP5) resistant monoclonal antibody, hybridoma cell strain and application

The invention discloses a haemophilus parasuis outer membrane protein P5 (OMP5) resistant monoclonal antibody, a hybridoma cell strain and an application. The hybridoma cell strain is preserved in the China center for type culture collection (CCTCC), and the preservation serial number is CCTCCC2012135. The monoclonal antibody prepared by the hybridoma cell strain is good in specificity, high in valence, high in generality, free from cross reaction with swine Escherichia coli, swine pasteurella, swine pleuropneumonia actinobacillus, streptococcus suis and swine bordetella bacilli, capable of detecting haemophilus parasuis with different serotypes and widely applicable to etiology diagnosis, serology detection and immunology detection and prevention of haemophilus parasuis diseases, and the enzyme-linked immuno sorbent assay (ELISA) antibody valence can reach 1:204800 after purification.
Owner:广东省农业科学院兽医研究所

Canine combination vaccines

ActiveUS20080226670A1SsRNA viruses negative-senseAntibacterial agentsDiseaseTracheobronchitis
This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.
Owner:ZOETIS SERVICE LLC

Modified pertussis toxin

The development of subunits and subunit analogs of the Bordetella exotoxin by recombinant DNA techniques provides vaccine products that retain their biological activity, are highly immunogenic, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits can result in products that retain immunogenicity, yet are free of enzymatic activity associated with toxin of reactogenicity.
Owner:AMGEN INC

Triple inactivated vaccine for rabbit viral hemorrhagic disease, pasteurellosis and bordetella disease and preparation method of vaccine

The invention relates to a triple inactivated vaccine for rabbit viral hemorrhagic disease, pasteurellosis and bordetella disease and a preparation method of the vaccine. The effective components of the vaccine comprise VP60 protein antigen of rabbit viral hemorrhagic disease virus, inactivated pasteurella multocida QLT-1 strain and bordetella bronchiseptica JN01 strain antigen. The triple inactivated vaccine has fast generation of protective antibody after immunization and high immune attack protection rate, with the attack protection rate for rabbit viral hemorrhagic disease virus AV-34 strain, pasteurella multocida QLT-1 strain and bordetella bronchiseptica JN01 strain all reaching above 80%. The results show that the vaccine is safe and reliable, and can be used for preventing the occurrence of rabbit viral hemorrhagic disease (rabbit plague), rabbit pasteurella multocida disease (type A) and rabbit bronchisepticaemia Bordetella disease.
Owner:QILU ANIMAL HEALTH PROD

Method of separating protective components of Bordetella pertussis

PCT No. PCT / JP95 / 00830 Sec. 371 Date Oct. 13, 1995 Sec. 102(e) Date Oct. 13, 1995 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95 / 29934 PCT Pub. Date Nov. 9, 1995To provide a method of efficiently separate protective components of Bordetella pertussis. On the basis of differences in adsorbability to calcium phosphate gel formed by adding calcium ions to a Bordetella pertussis culture in the presence of excess phosphate ions, protective components of Bordetella pertussis are separated from the Bordetella pertussis culture. Traditionally, protective components of Bordetella pertussis have been separated using different purification methods for the respective components. According to the present invention, the use of the same means of purification for all subject components makes it possible to purify each component with high efficiency and high recovery rate, an aspect very advantageous for industrial production. It is also possible to efficiently produce an improved purified pertussis component vaccine comprising an effective combination of pertussis filamentous hemagglutinin (FHA), pertactin (PRN, 69K-OMP), pertussis fimbriae (FIM) and pertussis toxin (PT).
Owner:TAKEDA PHARMA CO LTD

Compound microbial inoculum resistant to high-temperature decomposition for crop straws and preparation method thereof

InactiveCN109504633AShorten the maturity timeGuaranteed to return to the field after decayBio-organic fraction processingFungiBacillus licheniformisDecomposition
The invention relates to a fermentation microbial inoculum, in particular to a compound microbial inoculum resistant to high-temperature decomposition for crop straws and a preparation method thereof.The composite microbial inoculum comprises YM bacteria, bacillus licheniformis, alcaligenes, agaricus bisporus, bordetella, streptomyces, coccidioides immitis, aspergillus flavus and trichoderma koningii. The components are evenly mixed in proportion to obtain a final product. The compound microbial inoculum provided by the invention can rapidly decompose crop straws and shorten the time for decomposing the straws; in the prior art, the time for decomposing the straws is generally more than 10 days; through the treatment with the compound microbial inoculum resistant to ultra-high temperaturedecomposition, straws can be decomposed and returned to the field within 7 days, and the time interval between postharvest and planting is shortened; and a fermentation process has no odor and fullykills pathogenic bacteria and pathogenic microorganisms.
Owner:ZHENGZHOU INST OF TECH

Uses of Phyllanthus emblica, and Phyllanthus emblica composition and uses thereof

InactiveCN109276602AExpand the scope of antibacterial applicationGrowth inhibitionAntibacterial agentsDigestive systemEscherichia coliBacteroides
The invention discloses applications of Phyllanthus emblica or Phyllanthus emblica and a Phyllanthus emblica composition in preparation of products for preventing and / or treating at least one of mastitis, diarrhea and porcine respiratory diseases, and further provides antibacterial effects of Phyllanthus emblica or Phyllanthus emblica extract and the Phyllanthus emblica composition, wherein the Phyllanthus emblica or Phyllanthus emblica extract and the Phyllanthus emblica composition can effectively inhibit the growth of one or a variety of bacteria selected from Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas, Salmonella choleraesuis, Escherichia coli, Group A beta-hemolytic streptococcus, Streptococcus suis, Bordetella, Pasteurella multocida, Salmonella enterica, Staphylococcus haemolyticus, Enterococcus faecalis and Erysipelothrix rhusiopathiae, and the effectiveness of the uses are proved through experiments so as to expanded the applications of Phyllanthus emblica andthe Phyllanthus emblica composition.
Owner:SICHUAN ANIMAL SCI ACAD

Defective entities and uses therefor

The present invention discloses the structure and sequence of aroQ from Bordetella pertussis, which are useful inter alia for the production of the genetically modified attenuated Bordetella strains of the present invention and for detecting and isolating variant aroQ genes and expression products. The present invention also discloses attenuated Bordetella strains of pathogenic origin, and more particularly genetically modified Bordetella strains, which have been attenuated by disruption or inactivation of the aroQ gene. The genetically modified Bordetella strain of the present invention has a reduced capacity to propagate in a mammalian host, but remains viable in the host for a period of time sufficient to induce a protective immune response against the natural pathogenic Bordetella counterpart. The present invention is also directed to the use of such genetically modified Bordetella strains in immunopotentiating compositions for treating and / or preventing inter alia Bordetella infections, and particularly pathogenic infections, caused by Bordetella.
Owner:SOUTHERN QUEENSLAND UNIV OF

Application of phage depolymerase ORF38 protein in pasteurella multocida capsule typing identification

The invention discloses application of phage depolymerase ORF38 protein in pasteurella multocida capsule typing identification, wherein the amino acid sequence of the protein is shown as SEQ ID No.2, and the nucleotide sequence for coding the protein is shown as SEQ ID No.1. According to the invention, it is found for the first time that the phage depolymerase ORF38 protein only has a splitting effect on PmD and does not have a splitting effect on pasteurella multocida (including A, B, E and F) of other capsule serotypes and other bacteria such as escherichia coli, salmonella, haemophilus parasuis, bordetella bronchii, streptococcus, staphylococcus aureus and the like, so that the phage depolymerase ORF38 protein can be used for PmD capsule typing identification; and the phage depolymerase ORF38 protein has the advantages of simplicity, rapidness, accuracy and the like.
Owner:INST OF ANIMAL SCI & VETERINARY MEDICINE SHANDONG ACADEMY OF AGRI SCI

Monoclonal antibody of hemophilus parasuis resistant OMP5 (outer membrane protein), hybridoma cell strain HPS1E2 and application

The invention discloses a monoclonal antibody of hemophilus parasuis resistant OMP5 (outer membrane protein), a hybridoma cell strain HPS1E2 and application. The hybridoma cell strain is preserved in a Chinese typical culture preservation center, and the preservation number is CCTCCC2012138. The monoclonal antibody prepared with the hybridoma cell strain is fine in specificity, high in valence and high in universality, is not in cross reaction with swine Escherichia coli, swine pasteurella, actinobcillus pleuropneumoniae, streptococcus suis and swine bordetella, the valence of the purified ELISA (enzyme-linked immuno sorbent assay) antibody can reach 1:409600, hemophilus parasuis with different serotypes can be detected, and the monoclonal antibody can be widely used for etiology diagnosis, serological test, immunological test, prevention and treatment and the like of hemophflussuis.
Owner:广东省农业科学院兽医研究所

Bordetella adenylate cyclase toxin vaccines and neutralizing antibodies

The present disclosure describes immunogenic portions of Bordetella adenylate cyclase toxin (ACT), and neutralizing antibodies specific for such polypeptides. The antibodies can be used for diagnosis and anti-Bordetella therapies. Further provided are vaccine compositions including recombinant Bordetella adenylate cyclase toxin polypeptides.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Canine vaccines

InactiveUS20080175860A1SsRNA viruses negative-senseAntibacterial agentsDiseaseTracheobronchitis
This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona.
Owner:PFIZER INC +1

Vectors for molecule delivery to CD11b expressing cells

The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions, and to a new vector for molecule delivery to CD11b expressing cells.
Owner:INST PASTEUR +1

Vaccines for the prevention of infections with bordetella

A vaccine for the prevention of infections with Bordetella, comprising at least outer membrane vesicles (OMVs) of B. parapertussis, excipients and / or adjuvants. Bordetella may be, for example, B. pertussis or B. parapertussis. The vaccine can comprise adjuvants, for example, aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof.In another preferred embodiment, the vaccine for the prevention of infections with Bordetella comprises at least outer membrane vesicles (OMVs) of B. pertussis and the lipopolysaccharide of B. parapertussis, excipients and / or adjuvants. The vaccine can comprise between 3 to 20 μg per dose of OMVs from B. pertussis and between the amount equivalent to 107 and 1010 bacteria per dose of lipopolysaccharide of B. parapertussis. The adjuvant can be aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. The Tdap vaccine exhibits cross activity.
Owner:CONSEJO NAT DE INVESTIGACIONES CIENTIFICAS Y TECH CONICET +2

Fermentation process

A process for fermenting Bordetella species comprising incubating a sample of bacteria of a Bordetella species in a first environment under at least one bvg (Bordetella virulence genes) modulating condition, for at least 5 generations, to produce a mature culture, and then incubating the mature culture in a second environment in the absence of the at least one bvg modulating condition.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products